KDDF

Season 2 (2021-2030)

Respiratory - Discovery (11)

	Modality	Indication	Targets	Stage	Company	Project No.
1	Development of antibodies to induce lung regeneration for the treatment of emphysema
1	Antibody	Pulmonary emphysema	Robo1	Hit	Asan Medical Center	HN21C0202
2	Development of therapeutic fully human monoclonal antibody FBPF-11X as lead compound for pulmonary fibrosis
2	Antibody	Pulmonary fibrosis	FBFP-101-T	Lead	FNCT Biotech	HN22C0683
3
3	Other-Bio.	Bronchopulmonary Dysplasia(BPD)	Ago2	Lead	Samsung Medical Center	HN22C0414
4	Derivation of lead candidates for idiopathic  pulmonary fibrosis treatment through inhalant  optimization of integrin selective binding peptide
4	rProtein	IPF	Integrin αVβ-3,5,6	Lead	NEXEL	HN22C0012
5	Development of drug candidate against respiratory infection using Foxj1 as a target
5	Small molecules	Pneumonia	Foxj1	Lead	Chonnam National University	HN21C0513
6	Elicitation of lead compounds for the treatment of chronic obstructive pulmonary disease targeting leucotriene B4 receptor BLT2
6	Small molecules	COPD	BLT2	Lead	Korea university	HN21C0996
7	Study on lead generation for IPF (idiopathic pulmonary fibrosis) drug based on AI platform
7	Small molecules	IPF	CHIT1	Lead	INNOVO Therapeutics	HN21C0205
8	Development of CSF3 targeted Pre-clinical Candidate Human Monoclonal Antibody FB-101 for Pulmonary Fibrosis
8	Antibody	Idiopathic Pulmonary Fibrosis	CSF3	Candidate	FNCT Biotech, Inc.	RS-2024-00461975
9	Discovery of a novel small-molecule drug candidate targeting IL-33
9	Small molecules	Asthma	IL-33	Candidate	Azcuris Co., Ltd.	RS-2024-00333140
10	Discovery of a ‘First.In.Class’ New Drug for IPF Treatment
10	Small molecules	Idiopathic pulmonary fibrosis	ARPC2	Candidate	SapiensBio.Inc	RS-2023-00283815
11	ATB-610: Small molecule developing as a inhaler with reducing toxicity by inhibiting ALK5 selectively for IPF treatment
11	Small molecules	IPF	ALK5	Candidate	Autotelic Bio	RS-2022-00165740

BACK